nemolizumab
galderma
['nemolizumab', 'olympia 2', 'derm']
what a huge honor to present at the late breaker session to provide the first glimpse of data from the olympia 2 phase 3 trial of nemolizumab monotherapy in prurigo nodularis! there s a revolution going on in pn, #prurigo in #primetime! #aad23latebreaker #dermtwitter 
Associate Professor, Johns Hopkins Medicine | Dermatologist | Translational Scientist | Itch Researcher | Inflammatory Skin Diseases | Skin of Color